How should Linzess (linaclotide) be dosed and administered, and what are its contraindications and common adverse effects for irritable bowel syndrome with constipation and chronic constipation in adults and children?

Linzess (Linaclotide) Dosing, Administration, and Safety Profile

For adults with IBS-C, use linaclotide 290 mcg once daily; for chronic idiopathic constipation (CIC), use 145 mcg once daily (or 72 mcg if tolerability is a concern); and for pediatric functional constipation (ages 6-17), use 72 mcg once daily—all taken on an empty stomach at least 30 minutes before the first meal of the day. 1

Dosing by Indication

Adults

IBS-C (Irritable Bowel Syndrome with Constipation):

• 290 mcg orally once daily 1
• This higher dose is specifically FDA-approved for IBS-C because it addresses both constipation and the characteristic abdominal pain/discomfort of IBS 2

CIC (Chronic Idiopathic Constipation):

• 145 mcg orally once daily as the standard dose 1
• 72 mcg orally once daily may be used based on individual presentation or tolerability concerns 2, 1
• The 2023 AGA-ACG guidelines strongly recommend linaclotide over no treatment for adults with CIC who don't respond to over-the-counter agents (strong recommendation, moderate certainty evidence) 2

Pediatric Patients (6-17 years)

Functional Constipation:

• 72 mcg orally once daily 1
• This represents an important advancement as historically there were no FDA-approved pharmacologic options specifically evaluated for pediatric IBS-C 3

Administration Instructions

Critical timing and preparation details:

• Take on an empty stomach at least 30 minutes before the first meal at approximately the same time each day 2, 1
• Do not crush or chew the capsule or its contents 1
• If a dose is missed, skip it and take the next dose at the regular time—never double dose 1

For patients unable to swallow capsules whole:

The capsule can be opened and administered via three methods 1:

1. With applesauce: Open capsule, sprinkle entire contents on one teaspoon of room-temperature applesauce, consume immediately without chewing beads
2. With water (oral): Open capsule into 30 mL room-temperature water, swirl for 20 seconds, swallow immediately (beads remain visible but drug dissolves off surface)
3. Via NG/G-tube: Mix beads with 30 mL water, draw into catheter-tipped syringe, dispense rapidly (10 mL/10 seconds), flush tube with minimum 10 mL water

Contraindications

Absolute contraindications:

1. Patients less than 2 years of age 1

   • BLACK BOX WARNING: Linaclotide caused deaths due to dehydration in neonatal mice 1
   • This is the most critical safety consideration

2. Known or suspected mechanical gastrointestinal obstruction 2

Adverse Effects

Most common adverse effect:

Diarrhea is the predominant and dose-related adverse effect 2, 4:

• Reported in 16-20% of clinical trial participants 5
• Led to treatment discontinuation in approximately 4-4.7% of patients 2, 4
• Majority (90.5%) of diarrhea cases were mild to moderate 4
• Risk is 3 times higher compared to placebo (RR 3.35,95% CI 2.09-5.36) 2

Other common adverse effects (≥2% in adults):

• Abdominal pain 1
• Flatulence 1
• Abdominal distension 1

Important safety considerations:

• Serious adverse events were rare and similar across treatment groups 4
• No serious adverse events of diarrhea were reported 4
• The most common reasons for discontinuation over the first year were actually loss of efficacy and insurance coverage barriers, not adverse events 2

Mechanism and Clinical Benefits

Linaclotide is a guanylate cyclase-C agonist that increases cyclic GMP concentrations, resulting in 2:

• Luminal chloride and bicarbonate secretion
• Increased intestinal fluid
• Accelerated GI transit
• Reduced visceral hypersensitivity (particularly relevant for IBS-C)

Evidence of efficacy from high-quality trials:

• Increases complete spontaneous bowel movements (CSBMs) by 1.37 per week (95% CI 1.07-1.95) 2
• Increases spontaneous bowel movements (SBMs) by 1.97 per week (95% CI 1.59-2.36) 2
• Improves stool consistency significantly 2
• Increases global relief rates (RR 1.96,95% CI 1.63-2.35) 2
• Particularly effective for abdominal bloating, discomfort, and pain in IBS-C 2

Clinical Pearls and Pitfalls

When to use which dose:

• The 290 mcg dose approved for IBS-C may be useful in CIC patients who have coexisting abdominal discomfort, pain, and bloating, recognizing that CIC and IBS-C often overlap and are indistinguishable in practice 2

Duration of treatment:

• Clinical trials evaluated 12-week treatment periods, but the FDA label does not provide a treatment duration limit 2
• Can be used as replacement or adjunct to OTC agents 2

Managing diarrhea:

• If severe diarrhea occurs, suspend dosing and rehydrate the patient 1
• Consider dose reduction (e.g., from 145 mcg to 72 mcg in CIC) if tolerability is an issue 1

Special populations:

• No clear differences in outcomes for patients older than 65 years, though sample sizes were limited 2
• Minimal systemic absorption makes drug interactions unlikely 5